A Randomised, Single-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Ascending Administration of Otelixizumab in Subjects With Type 1 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 30 May 2014 Planned End Date changed from 1 Jul 2015 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2011 Additional location (USA) identified as reported by ClinicalTrials.gov.